Tsinghua Holdings subsidiary CapitalBio Corporation, headquartered in Beijing, launched an industrialization base in Shanghai International Medical City, on Aug 8, to expand its business to the eastern part of China. 

At present, CapitalBio's subsidiaries CapitalBio Technology, CapitalBio eHealth, CapitalBio Genomics, and CapitalBio Dx have settled their offices in the new Shanghai base. 

"We set out to forge the Shanghai base into CapitalBio's center and R&D hub in southern China, shaping it into a typical innovation base," said Xu Junquan, head of the Shanghai base of CapitalBio.

In line with CapitalBio's strategy and operational targets, the base is important to the company's future development in East China.

Cheng Jing (L), president of CapitalBio, and Lu Xiaowei, general manager of Shanghai International Medical City, cut the ribbon at the launch ceremony. 

Established in 2000, CapitalBio has developed a complete industrial chain covering disease prediction, early warning and individual treatment. It has launched several industrialization bases across China, including Beijing and Chongqing. 

"Shanghai International Medical City is a new-concept medical research park. It is also an important area of the Shanghai Zhangjiang Hi-Tech Park, a State-level innovation demonstration zone," said Lu Xiaowei, general manager of the city.

Guests of the ceremony visit CapitaBio's Shanghai industrialization base. 

Lu welcomed the settlement of CapitalBio, expressing her anticipation for fruitful cooperation between CapitalBio and the city. 

CapitalBio signed strategic cooperation agreements with several industry giants, including ThermoFisher Scientific and New Chinalife Insurance.